Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: An immunotherapy effect analysis in Rasmussen encephalitis

Fig. 1

Sampling in the context of disease duration and immunotherapy. Disease duration defined the interval from the appearance of the first symptom until functional hemispherotomy in every patient; the correct diagnosis was made after a delay from the first symptom. The prodromal phase of the disease characterized infrequent seizures and no hemiparesis. The seizure frequency strikingly increased, all patients developed intractable epilepsy, and an individual functional decline in the affected hemisphere and its atrophy became evident in an acute phase of the disease. The time of a transition to the residual phase was not clearly clinically recognizable, and all patients suffered from intractable epilepsy until neurosurgery. The clinical outcome in every patient at the time of disease diagnosis and then at the time of neurosurgery is displayed using modified Rankin scale (mRS); the numbers in squares express mRS scores. In addition, immunotherapies are shown, and the type and time of the sample withdrawals are noted in every patient

Back to article page